arrow
M

Mark Slee

Flinders University
H指数:43
被引数:7,890

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Causal effects of multiple sclerosis therapies in left-truncated registry data

多发性硬化疗法在左截断登记数据中的因果效应

2026-07-210
PRE
Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study

在高危和低危侵袭性多发性硬化患者中保留神经功能:一项观察性队列研究

2026-04-040
OAAI
Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024)

四年之后:MSBase妊娠、新生儿结局及女性健康登记册(2020–2024)中报告的妊娠与分娩结局

2025-07-070
PRE
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis

克拉屈滨与芬戈莫德,那他珠单抗,ocrelizumab和阿仑单抗在复发缓解型多发性硬化症中的疗效比较

2024-08-010
PRE
Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study

常规CSF参数可作为多发性硬化症病程的预测指标: 一项MSBase队列研究

2024-04-030
OA
Evaluation of Cell-Specific Epigenetic Age Acceleration in People With Multiple Sclerosis

多发性硬化症患者细胞特异性表观遗传年龄加速的评估

2023-08-155
OAAI
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial

多种疾病改善疗法在复发缓解型多发性硬化症中的有效性: 模拟多臂随机试验的因果推断

2023-07-062
PRE
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

继发性进行性多发性硬化症的风险由地理位置决定,但可以改变

BRAIN
IF11.7
2023-06-275
OAAI
Disability accrual in primary and secondary progressive multiple sclerosis

原发性和继发性进行性多发性硬化症的残疾累积

2023-04-174
OA
Evaluating the Ability of Open-Source Artificial Intelligence to Predict Accepting-Journal Impact Factor and Eigenfactor Score Using Academic Article Abstracts: Cross-sectional Machine Learning Analysis

使用学术文章摘要评估开源人工智能预测接受期刊影响因子和特征因子得分的能力: 横断面机器学习分析

2023-03-071
OA
Not all roads lead to the immune system: the genetic basis of multiple sclerosis severity
BRAIN
IF11.7
2022-11-3020
PRE
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis
2022-10-2521
OA
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis
2022-10-1910
PRE
Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis An International Registry Study
2022-06-1418
OA
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis
2022-05-305
OAAI